Power Law company profile

ADMA Biologics

Biotech & Life Sciences · Ramsey, United States · Founded 2004 · IPO 2013 Unicorn

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics

Valuation

$2.37B

Market cap · May/2026

Revenue

$510M

Latest reported FY

EBITDA

$317M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where ADMA Biologics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States99.6%

🏳️ Rwanda0.4%

2 countries shown

Web traffic by country

13K monthly visits
across markets

🇺🇸 United States76.2%

🇦🇺 Australia13.8%

🇬🇧 United Kingdom9.2%

🇨🇦 Canada8.5%

🇮🇳 India7.7%

Top 5 markets shown

Patent intelligence

$44M patent portfolio · 9 active families

Estimated portfolio value

$44M

1.8% of market cap · 2.9× smaller than top peer Vir Biotechnology ($126M)

9 active patent families

Where ADMA Biologics innovates VirologyAntibody titerPassive ImmunizationsBlood plasmaGlobulin

Where ADMA Biologics concentrates vs peers

Each axis is a top-10 topic across ADMA Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about ADMA Biologics

An AI-synthesized read of the highest-engagement posts about ADMA Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ADMA Biologics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles